S&P 500   4,311.27 (-0.35%)
DOW   33,954.29 (-0.60%)
QQQ   340.93 (-0.05%)
AAPL   165.76 (+4.11%)
MSFT   299.21 (-0.21%)
FB   294.82 (+0.06%)
GOOGL   2,586.05 (+0.23%)
AMZN   2,788.77 (-0.14%)
TSLA   825.58 (-0.42%)
NVDA   216.12 (-1.51%)
BABA   110.40 (-1.24%)
NIO   19.84 (-6.02%)
AMD   100.94 (-1.62%)
CGC   6.76 (-1.31%)
MU   75.96 (-3.51%)
GE   89.75 (-0.17%)
T   24.43 (+1.29%)
F   19.16 (-1.99%)
DIS   134.97 (-0.33%)
AMC   13.89 (-4.34%)
PFE   53.65 (+0.52%)
ACB   3.73 (-1.58%)
BA   185.67 (-2.15%)
S&P 500   4,311.27 (-0.35%)
DOW   33,954.29 (-0.60%)
QQQ   340.93 (-0.05%)
AAPL   165.76 (+4.11%)
MSFT   299.21 (-0.21%)
FB   294.82 (+0.06%)
GOOGL   2,586.05 (+0.23%)
AMZN   2,788.77 (-0.14%)
TSLA   825.58 (-0.42%)
NVDA   216.12 (-1.51%)
BABA   110.40 (-1.24%)
NIO   19.84 (-6.02%)
AMD   100.94 (-1.62%)
CGC   6.76 (-1.31%)
MU   75.96 (-3.51%)
GE   89.75 (-0.17%)
T   24.43 (+1.29%)
F   19.16 (-1.99%)
DIS   134.97 (-0.33%)
AMC   13.89 (-4.34%)
PFE   53.65 (+0.52%)
ACB   3.73 (-1.58%)
BA   185.67 (-2.15%)
S&P 500   4,311.27 (-0.35%)
DOW   33,954.29 (-0.60%)
QQQ   340.93 (-0.05%)
AAPL   165.76 (+4.11%)
MSFT   299.21 (-0.21%)
FB   294.82 (+0.06%)
GOOGL   2,586.05 (+0.23%)
AMZN   2,788.77 (-0.14%)
TSLA   825.58 (-0.42%)
NVDA   216.12 (-1.51%)
BABA   110.40 (-1.24%)
NIO   19.84 (-6.02%)
AMD   100.94 (-1.62%)
CGC   6.76 (-1.31%)
MU   75.96 (-3.51%)
GE   89.75 (-0.17%)
T   24.43 (+1.29%)
F   19.16 (-1.99%)
DIS   134.97 (-0.33%)
AMC   13.89 (-4.34%)
PFE   53.65 (+0.52%)
ACB   3.73 (-1.58%)
BA   185.67 (-2.15%)
S&P 500   4,311.27 (-0.35%)
DOW   33,954.29 (-0.60%)
QQQ   340.93 (-0.05%)
AAPL   165.76 (+4.11%)
MSFT   299.21 (-0.21%)
FB   294.82 (+0.06%)
GOOGL   2,586.05 (+0.23%)
AMZN   2,788.77 (-0.14%)
TSLA   825.58 (-0.42%)
NVDA   216.12 (-1.51%)
BABA   110.40 (-1.24%)
NIO   19.84 (-6.02%)
AMD   100.94 (-1.62%)
CGC   6.76 (-1.31%)
MU   75.96 (-3.51%)
GE   89.75 (-0.17%)
T   24.43 (+1.29%)
F   19.16 (-1.99%)
DIS   134.97 (-0.33%)
AMC   13.89 (-4.34%)
PFE   53.65 (+0.52%)
ACB   3.73 (-1.58%)
BA   185.67 (-2.15%)
NASDAQ:VINC

Vincerx Pharma Stock Forecast, Price & News

$6.66
-0.11 (-1.62%)
(As of 01/28/2022 10:10 AM ET)
Add
Compare
Today's Range
$6.61
▼
$6.70
50-Day Range
$6.77
▼
$12.56
52-Week Range
$6.23
▼
$26.75
Volume
301 shs
Average Volume
149,766 shs
Market Capitalization
$140.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive VINC News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.


Vincerx Pharma logo

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Headlines

Vincerx Pharma (NASDAQ:VINC) Receives New Coverage from Analysts at HC Wainwright
January 14, 2022 |  americanbankingnews.com
Bullish Vincerx Pharma, Inc. (NASDAQ:VINC) insiders filled their treasuries with US$741k worth of stock over last year
December 28, 2021 |  nasdaq.com
Vincerx Pharma, Inc. (NASDAQ:VINC) insiders placed bullish bets worth US$741k in the last 12 months
December 28, 2021 |  finance.yahoo.com
Cantor Fitzgerald Initiates Coverage On Vincerx Pharma with Overweight Rating, Announces Price Target of $25
December 24, 2021 |  benzinga.com
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
December 17, 2021 |  finance.yahoo.com
Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting
November 4, 2021 |  finance.yahoo.com
Vincerx Pharma Announces $50 Million Private Placement
September 16, 2021 |  finance.yahoo.com
Vincerx Pharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
September 7, 2021 |  finance.yahoo.com
Vincerx Pharma Inc.
August 21, 2021 |  barrons.com
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
August 12, 2021 |  finance.yahoo.com
Is Vincerx Pharma, Inc. (VINC) A Good Stock To Buy?
July 30, 2021 |  finance.yahoo.com
Thursday 7/1 Insider Buying Report: VINC, FULC
July 1, 2021 |  nasdaq.com
Insider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Independent Director Just Bought US$126k Worth Of Shares
July 1, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VINC
Previous Symbol
CUSIP
N/A
CIK
1796129
Web
vincerapharma.com
Phone
N/A
Fax
N/A
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.81 per share
Price / Book
3.68

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-16.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-76.19%
Return on Assets
-49.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.90
Quick Ratio
4.90

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
21,058,000
Free Float
10,740,000
Market Cap
$140.25 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/28/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.83 out of 5 stars

Medical Sector

41st out of 1,417 stocks

Pharmaceutical Preparations Industry

13th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -












Vincerx Pharma (NASDAQ:VINC) Frequently Asked Questions

Is Vincerx Pharma a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vincerx Pharma stock.
View analyst ratings for Vincerx Pharma or view top-rated stocks.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) announced its quarterly earnings results on Friday, November, 12th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.23.
View Vincerx Pharma's earnings history.

What price target have analysts set for VINC?

6 analysts have issued twelve-month target prices for Vincerx Pharma's stock. Their forecasts range from $24.00 to $30.00. On average, they expect Vincerx Pharma's share price to reach $26.67 in the next twelve months. This suggests a possible upside of 303.4% from the stock's current price.
View analysts' price targets for Vincerx Pharma or view top-rated stocks among Wall Street analysts.

Who are Vincerx Pharma's key executives?

Vincerx Pharma's management team includes the following people:
  • Dr. Ahmed M. Hamdy, Founder, Chairman & CEO (Age 56, Pay $622.05k) (LinkedIn Profile)
  • Dr. Raquel E. Izumi, Founder, Pres, COO, Sec. & Director (Age 51, Pay $652.84k) (LinkedIn Profile)
  • Mr. Alexander A. Seelenberger M.B.A., MBA, Chief Financial Officer (Age 42, Pay $405.46k)
  • Mr. Stuart Hwang Ph.D., Chief Bus. Officer & Founder
  • Mr. Tom C. Thomas, Founder, Gen. Counsel & Chief Legal Officer (Age 61) (LinkedIn Profile)
  • Dr. John C. Byrd M.D., Founder & Chairman of Scientific Advisory Board
  • Dr. Xiaoming Zhang Ph.D., Chief Technical Officer (Age 57)
  • Dr. Hans-Georg Lerchen Ph.D., Chief Scientific Officer
  • Dr. Hermes Garban M.D., Ph.D., Chief Medical Officer (Age 53)
  • Dr. David Nganele M.B.A., Ph.D., Head of Early Devel.

What is Vincerx Pharma's stock symbol?

Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC."

Who are Vincerx Pharma's major shareholders?

Vincerx Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.30%) and Hollencrest Capital Management (0.05%). Company insiders that own Vincerx Pharma stock include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Laura I Bushnell, Raquel E Izumi and Tom C Thomas.
View institutional ownership trends for Vincerx Pharma.

Which institutional investors are buying Vincerx Pharma stock?

VINC stock was purchased by a variety of institutional investors in the last quarter, including Hollencrest Capital Management, and Russell Investments Group Ltd.. Company insiders that have bought Vincerx Pharma stock in the last two years include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Laura I Bushnell, Raquel E Izumi, and Tom C Thomas.
View insider buying and selling activity for Vincerx Pharma or or view top insider-buying stocks.

How do I buy shares of Vincerx Pharma?

Shares of VINC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vincerx Pharma's stock price today?

One share of VINC stock can currently be purchased for approximately $6.61.

How much money does Vincerx Pharma make?

Vincerx Pharma has a market capitalization of $139.19 million.

How many employees does Vincerx Pharma have?

Vincerx Pharma employs 28 workers across the globe.

What is Vincerx Pharma's official website?

The official website for Vincerx Pharma is vincerapharma.com.

Where are Vincerx Pharma's headquarters?

Vincerx Pharma is headquartered at 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.